OxfordVR is a digital therapeutics company that develops evidence-based immersive treatments using virtual reality for serious mental illness. Its treatments are reshaping the future of mental healthcare, fusing deep scientific evidence with emerging technology to create powerful new therapeutic tools for some of the world’s most challenging mental health conditions. The company was founded in 2016 and is based in Austin, Texas.

Cognoa is developing digital products intended to support healthcare providers in expediting diagnosis with the goal of improving access to timely intervention for children and families, starting with autism spectrum disorder (ASD).

We are developing digital diagnostic and therapeutic products with the goal of enabling earlier and more equitable care for behavioral health conditions.

Our recent 350 patient clinical trial, published in Lancet Psychiatry, shows positive effects in psychosis patients – reducing avoidance, distress, and paranoia

Cognoa seeks to help improve the lives and outcomes of children and their families living with behavioral health conditions. We strive to improve timely, equitable access to a diagnosis for caregivers with early concerns of developmental delay, including autism, to support opportunities for early intervention and improved outcomes for children and their families.